Eptifibatide-induced thrombocytopenia and thrombosis

Journal of Thrombosis and Thrombolysis

Volumn 22, Issue 2, 2006, Pages 151-154

  Epelman, Slava ^a   Nair, Deepu ^a   Downey, Ross ^a   Militello, Mike ^a   Askari, Arman T ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Eptifibatide; Glycoprotein IIb IIIa; Platelets; Thrombocytopenia; Thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ARGATROBAN; CLOPIDOGREL; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN;

AGED; ARTICLE; CASE REPORT; CORONARY STENT; DATA ANALYSIS; DATA BASE; DEEP VEIN THROMBOSIS; HEART INFARCTION; HUMAN; HYPOXIA; LUNG EMBOLISM; MALE; MEDICAL LITERATURE; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION; THROMBOCYTOPENIA; THROMBOPHLEBITIS; THROMBOSIS;

AGED; HUMANS; MALE; MYOCARDIAL INFARCTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; THROMBOCYTOPENIA; VENOUS THROMBOSIS;

EID: 33749169202     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11239-006-8785-1     Document Type: Article

References (28)

1. Coller BS (1990) Platelets and thrombolytic therapy. N Engl J Med 322(1):33-42
2. Scarborough RM, Rose JW, Hsu MA, Phillips DR, Fried VA, Campbell AM, et al (1991) Barbourin. A GPIIb-IIIa-specific integrin antagonist from the venom of Sistrurus m. barbouri. J Biol Chem 266(15):9359-9362
3. Pytela R, Pierschbacher MD, Ginsberg MH, Plow EF, Ruoslahti E (1986) Platelet membrane glycoprotein IIb/IIIa: Member of a family of Arg-Gly-Asp-specific adhesion receptors. Science 231(4745):1559-1562
4. Topol EJ, Ferguson JJ, Weisman HF, Tcheng JE, Ellis SG, Kleiman NS, et al (1997) Long-term protection from myocardial ischemic events in a randomized trial of brief integrin beta3 blockade with percutaneous coronary intervention. EPIC Investigator Group. Evaluation of Platelet IIb/IIIa Inhibition for Prevention of Ischemic Complication. JAMA 278(6):479-484
5. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes (1998) The PURSUIT Trial Investigators. Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy. N Engl J Med 339(7):436-443
6. Aster RH (2005) Immune thrombocytopenia caused by glycoprotein IIb/IIIa inhibitors. Chest 127(2 Suppl):53S-59S
7. Tcheng JE, Kereiakes DJ, Lincoff AM, George BS, Kleiman NS, Sane DC, et al (2001) Abciximab readministration: Results of the ReoPro Readministration Registry. Circulation 104(8):870-875
8. Jubelirer SJ, Koenig BA, Bates MC (1999) Acute profound thrombocytopenia following C7E3 Fab (Abciximab) therapy: Case reports, review of the literature and implications for therapy. Am J Hematol 61(3):205-208
9. Fahdi IE, Saucedo JF, Hennebry T, Ghani M, Sadanandan S, Garza-Arreola L (2004) Incidence and time course of thrombocytopenia with abciximab and eptifibatide in patients undergoing percutaneous coronary intervention. Am J Cardiol 93(4):453-455
10. Topol EJ, Moliterno DJ, Herrmann HC, Powers ER, Grines CL, Cohen DJ, et al (2001) Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 344(25):1888-1894
11. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II (1997) Integrilin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 349(9063):1422-1428
12. O'Shea JC, Hafley GE, Greenberg S, Hasselblad V, Lorenz TJ, Kitt MM, et al (2001) Platelet glycoprotein IIb/IIIa integrin blockade with eptifibatide in coronary stent intervention: The ESPRIT trial: A randomized controlled trial. JAMA 285(19):2468-2473
13. Rezkalla SH, Hayes JJ, Curtis BR, Aster RH (2003) Eptifibatide-induced acute profound thrombocytopenia presenting as refractory hypotension. Catheter Cardiovasc Interv 58(1):76-79
14. Coons JC, Barcelona RA, Freedy T, Hagerty MF (2005) Eptifibatide-associated acute, profound thrombocytopenia. Ann Pharmacother 39(2):368-372
15. Salengro E, Mulvihill NT, Farah B (2003) Acute profound thrombocytopenia after use of eptifibatide for coronary stenting. Catheter Cardiovasc Interv 58(1):73-75
16. Yoder M, Edwards RF (2002) Reversible thrombocytopenia associated with eptifibatide. Ann Pharmacother 36(4):628-630
17. Tanaka KA, Vega JD, Kelly AB, Hanson SR, Levy JH (2003) Eptifibatide-induced thrombocytopenia and coronary bypass operation. J Thromb Haemost 1(2):392-394
18. Khaykin Y, Paradiso-Hardy FL, Madan M (2003) Acute thrombocytopenia associated with eptifibatide therapy. Can J Cardiol 19(7):797-801
19. Nagge J, Jackevicius C, Dzavik V, Ross JR, Seidelin P (2003) Acute profound thrombocytopenia associated with eptifibatide therapy. Pharmacotherapy 23(3):374-379
20. Greinacher A, Michels I, Mueller-Eckhardt C (1992) Heparin-associated thrombocytopenia: The antibody is not heparin specific. Thromb Haemost 67(5):545-549
21. Horsewood P, Warkentin TE, Hayward CP, Kelton JG (1996) The epitope specificity of heparin-induced thrombocytopenia. Br J Haematol 95(1):161-167
22. Ziporen L, Li ZQ, Park KS, Sabnekar P, Liu WY, Arepally G, et al (1998) Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. Blood 92(9):3250-3259
23. Bougie DW, Wilker PR, Wuitschick ED, Curtis BR, Malik M, Levine S, et al (2002) Acute thrombocytopenia after treatment with tirofiban or eptifibatide is associated with antibodies specific for ligand-occupied GPIIb/IIIa. Blood 100(6):2071-2076
24. Jennings LK, Haga JH, Slack SM (2000) Differential expression of a ligand induced binding site (LIBS) by GPIIb-IIIa ligand recognition peptides and parenteral antagonists. Thromb Haemost 84(6):1095-1102
25. Hayward CP (2004) Further complexities in diagnosing acquired thrombocytopenia: Unexpected parallels between antibody-mediated delayed thrombocytopenia with abciximab and heparin induced thrombocytopenia. Thromb Haemost 92(4):674-675
26. Curtis BR, Swyers J, Divgi A, McFarland JG, Aster RH (2002) Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets. Blood 99(6):2054-2059
27. Warkentin TE, Hayward CP, Boshkov LK, Santos AV, Sheppard JA, Bode AP, et al (1994) Sera from patients with heparin-induced thrombocytopenia generate platelet-derived microparticles with procoagulant activity: An explanation for the thrombotic complications of heparin-induced thrombocytopenia. Blood 84(11):3691-3699
28. Morel O, Jesel L, Chauvin M, Freyssinet JM, Toti F (2003) Eptifibatide-induced thrombocytopenia and circulating procoagulant platelet-derived microparticles in a patient with acute coronary syndrome. J Thromb Haemost 1(12):2685-2687